Your browser doesn't support javascript.
loading
Expression levels of ERCC1 and RRM1 mRNA and clinical outcome of advanced non-small cell lung cancer
Pakistan Journal of Medical Sciences. 2013; 29 (5): 1158-1161
de En | IMEMR | ID: emr-193686
Bibliothèque responsable: EMRO
Objective: We conducted a study to understand the genetic effect of ERCC1 and RRM1 on the chemotherapy response and clinical outcome of Non-Small Cell Lung Cancer [NSCLC]
Methods: The relative cDNA quantification for ERCC1 and RRM1 was conducted using a fluorescence-based real-time detection method among 294 NSCLC patients
Results: Compared with the internal reference gene beta-action, the median levels of ERCC1 and RRM1 expression were 2.43x10-2 and 0.11x10-2, respectively. Our study showed response to platinum-containing regimen chemotherapy was high in those with high ERCC1 expression, and the OR [95% CI] were 1.73[1.06-2.81]. An apparently high response to chemotherapy was decreased when patients were carrying both high expression of ERCC1 and RRM1, with OR [95% CI] of 2.57[1.21-4.90]. Patients with high expression of ERCC1 were associated with a longer OS by multivariate Cox proportional hazards model. Moreover, those carrying both high levels of ERCC1 and RRM1 were seem to have a longer OS when compared with those with low expression [HR=0.31, 95% CI=0.13-0.62 for OS]
Conclusion: This observation could be used in personalized chemotherapy, increase the response rate and prolonged survival time, and could encourage to explore the predictive value of other genes
Recherche sur Google
Indice: IMEMR Type d'étude: Prognostic_studies langue: En Texte intégral: Pak. J. Med. Sci. Année: 2013
Recherche sur Google
Indice: IMEMR Type d'étude: Prognostic_studies langue: En Texte intégral: Pak. J. Med. Sci. Année: 2013